A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 30 Dec 2014
At a glance
- Drugs Cediranib (Primary) ; RG 4733 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Glioma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer
- Focus Adverse reactions
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jul 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 11 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 May 2013 as reported by ClinicalTrials.gov.